Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

Q3 2025 Earnings Call Transcript November 6, 2025 Novavax, Inc. misses on earnings expectations. Reported EPS is $-1.24654 ...

Novavax Inc (NVAX) focuses on innovation and partnerships amid financial hurdles, aiming for profitability by 2028.

Gaithersburg-based Novavax raised its annual revenue forecast, banking on milestone payments from vaccine supply and licensing deals.

The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older. The Novavax vaccine is protein ...

The Biden administration announced Monday that it would purchase 3.2 million doses of the Novavax COVID-19 vaccine. It will be offered at no cost to states and federal partners. “We remain committed ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. On Aug. 22, the Food and Drug Administration ...

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...

Sept 15 (Reuters) - U.S. drug developer Novavax Inc (NVAX.O), opens new tab said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an ...

(Reuters) - Novavax Inc has begun a large late-stage study of its experimental COVID-19 vaccine in the United States, the drug developer said on Monday, after delaying the trial twice due to issues in ...

Total revenue of $70 million in the third quarter of 2025 Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date ...